Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLO NASDAQ:AXSM NASDAQ:BEAM NASDAQ:CRSP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$2.17-3.8%$2.30$0.98▼$4.46$747.25M0.468.19 million shs5.97 million shsAXSMAxsome Therapeutics$233.15+0.1%$194.00$96.09▼$238.56$12.00B0.59691,379 shs342,740 shsBEAMBeam Therapeutics$33.43+1.9%$28.02$15.35▼$36.44$3.45B2.262.02 million shs580,346 shsCRSPCRISPR Therapeutics$55.79-1.1%$51.20$35.38▼$78.48$5.39B1.741.85 million shs872,518 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics0.00%+14.80%+2.74%-19.06%+97.37%AXSMAxsome Therapeutics-0.72%-0.35%+25.85%+42.06%+126.07%BEAMBeam Therapeutics+2.85%+18.54%+7.33%+15.25%+94.31%CRSPCRISPR Therapeutics+5.32%+12.99%+8.30%-6.25%+51.48%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$2.17-3.8%$2.30$0.98▼$4.46$747.25M0.468.19 million shs5.97 million shsAXSMAxsome Therapeutics$233.15+0.1%$194.00$96.09▼$238.56$12.00B0.59691,379 shs342,740 shsBEAMBeam Therapeutics$33.43+1.9%$28.02$15.35▼$36.44$3.45B2.262.02 million shs580,346 shsCRSPCRISPR Therapeutics$55.79-1.1%$51.20$35.38▼$78.48$5.39B1.741.85 million shs872,518 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics0.00%+14.80%+2.74%-19.06%+97.37%AXSMAxsome Therapeutics-0.72%-0.35%+25.85%+42.06%+126.07%BEAMBeam Therapeutics+2.85%+18.54%+7.33%+15.25%+94.31%CRSPCRISPR Therapeutics+5.32%+12.99%+8.30%-6.25%+51.48%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.69Moderate Buy$8.52293.64% UpsideAXSMAxsome Therapeutics 2.90Moderate Buy$251.267.77% UpsideBEAMBeam Therapeutics 2.71Moderate Buy$46.8340.11% UpsideCRSPCRISPR Therapeutics 2.53Moderate Buy$65.4717.36% UpsideCurrent Analyst Ratings BreakdownLatest CRSP, ALLO, AXSM, and BEAM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026CRSPCRISPR Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/21/2026BEAMBeam Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.005/13/2026CRSPCRISPR Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$50.00 ➝ $56.005/13/2026BEAMBeam Therapeutics Tudor PickeringSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$39.005/13/2026BEAMBeam Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$40.00 ➝ $39.005/11/2026CRSPCRISPR Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$76.005/6/2026CRSPCRISPR Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$80.00 ➝ $82.005/5/2026AXSMAxsome Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$280.005/5/2026AXSMAxsome Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$225.00 ➝ $255.005/5/2026AXSMAxsome Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$242.00 ➝ $302.005/5/2026AXSMAxsome Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$270.00 ➝ $290.00(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$20K37,362.49N/AN/A$0.81 per share2.67AXSMAxsome Therapeutics$638.50M18.79N/AN/A$1.06 per share219.95BEAMBeam Therapeutics$139.74M24.61N/AN/A$11.32 per share2.95CRSPCRISPR Therapeutics$3.51M1,532.90N/AN/A$18.81 per share2.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$190.89M-$0.77N/AN/AN/AN/A-56.45%-40.36%8/12/2026 (Estimated)AXSMAxsome Therapeutics-$183.17M-$3.73N/A57.85N/A-26.59%-267.16%-28.53%8/3/2026 (Estimated)BEAMBeam Therapeutics-$79.99M-$0.68N/AN/AN/A-39.66%-29.00%-22.61%8/4/2026 (Estimated)CRSPCRISPR Therapeutics-$581.60M-$6.22N/AN/AN/A-13,856.54%-25.66%-20.39%8/3/2026 (Estimated)Latest CRSP, ALLO, AXSM, and BEAM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ALLOAllogene Therapeutics-$0.19-$0.18+$0.01-$0.18$0.00 millionN/A5/7/2026Q1 2026BEAMBeam Therapeutics-$1.0278-$0.91+$0.1178-$0.91$10.98 million$31.74 million5/4/2026Q1 2026AXSMAxsome Therapeutics-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million5/4/2026Q1 2026CRSPCRISPR Therapeutics-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 million3/31/2026Q1 2026CRSPCRISPR TherapeuticsN/A-$1.28N/A-$1.28N/A$1.46 million3/12/2026Q4 2025ALLOAllogene Therapeutics-$0.25-$0.17+$0.08-$0.17$0.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ABEAMBeam TherapeuticsN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A9.659.65AXSMAxsome Therapeutics2.271.391.32BEAMBeam Therapeutics0.0916.9916.99CRSPCRISPR Therapeutics0.3217.9717.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%AXSMAxsome Therapeutics81.49%BEAMBeam Therapeutics99.68%CRSPCRISPR Therapeutics69.20%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%AXSMAxsome Therapeutics20.60%BEAMBeam Therapeutics3.80%CRSPCRISPR Therapeutics4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310345.15 million299.60 millionOptionableAXSMAxsome Therapeutics38051.46 million40.86 millionOptionableBEAMBeam Therapeutics510102.88 million98.97 millionOptionableCRSPCRISPR Therapeutics46096.45 million92.30 millionOptionableCRSP, ALLO, AXSM, and BEAM HeadlinesRecent News About These CompaniesIs CRISPR Therapeutics (CRSP) One Of The Under-The-Radar Stocks With Massive Upside For 2026?May 29 at 8:21 AM | finance.yahoo.comCRISPR Therapeutics to Participate in Upcoming Investor ConferencesMay 28 at 12:04 PM | finance.yahoo.comCRISPR Therapeutics to Participate in Upcoming Investor ConferencesMay 28 at 8:00 AM | globenewswire.comBetter Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?May 25, 2026 | fool.comAssessing CRISPR Therapeutics (CRSP) Valuation After Narrower Q1 2026 Loss And Pipeline ProgressMay 24, 2026 | finance.yahoo.comBeck Bode LLC Buys New Shares in CRISPR Therapeutics AG $CRSPMay 24, 2026 | marketbeat.comCRISPR Therapeutics AG (CRSP) Reports Q1 2026 ResultsMay 23, 2026 | finance.yahoo.comBernstein Raises its Price Target on CRISPR Therapeutics (CRSP)May 22, 2026 | insidermonkey.comLeonteq Securities AG Makes New Investment in CRISPR Therapeutics AG $CRSPMay 22, 2026 | marketbeat.comCRISPR Therapeutics AG $CRSP Shares Bought by Northwestern Mutual Wealth Management Co.May 22, 2026 | marketbeat.comThese Are The Upcoming Catalysts For Crispr Therapeutics StockMay 21, 2026 | seekingalpha.com[Latest] Global Genome Editing Market Size/Share Worth USD 55.7 Billion by 2035 at a 17.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)May 21, 2026 | finance.yahoo.comCRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should KnowMay 19, 2026 | finance.yahoo.comCan Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?May 19, 2026 | finance.yahoo.comCRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should KnowMay 19, 2026 | zacks.comThe Best Stocks to Invest $3,000 In Right NowMay 19, 2026 | fool.comCRISPR Therapeutics Enters Second Phase As CASGEVY Uptake And Data BuildMay 18, 2026 | finance.yahoo.comCRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data LoomsMay 15, 2026 | marketbeat.comVanguard Group Inc. Reduces Stock Position in CRISPR Therapeutics AG $CRSPMay 13, 2026 | marketbeat.comCRISPR Therapeutics AG (CRSP) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comWhy Is CRISPR Therapeutics Stock in Focus Right NowMay 12, 2026 | kalkinemedia.comKNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026SpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20263 Stocks to Own If Gas Prices Keep RisingBy Dan Schmidt | May 16, 2026CRSP, ALLO, AXSM, and BEAM Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$2.16 -0.09 (-3.78%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Axsome Therapeutics NASDAQ:AXSM$233.15 +0.32 (+0.14%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Beam Therapeutics NASDAQ:BEAM$33.42 +0.63 (+1.91%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.CRISPR Therapeutics NASDAQ:CRSP$55.78 -0.60 (-1.06%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dollar Tree Keeps Winning After Family Dollar Divorce Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Meta's Manus Mess: Why China Blocked the Deal and What It Means Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
